Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) Shares Outstanding (Diluted Average) (2020 - 2025)

Revolution Medicines (RVMD) has 6 years of Shares Outstanding (Diluted Average) data on record, last reported at $190.1 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 13.35% year-over-year to $190.1 million; the TTM value through Dec 2025 reached $190.1 million, up 13.35%, while the annual FY2025 figure was $190.1 million, 13.35% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $190.1 million in Q4 2025 per RVMD's latest filing, roughly flat from $189.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $190.1 million in Q4 2025 and bottomed at $71.9 million in Q2 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $124.3 million, with a median of $106.9 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): increased 3.29% in 2022, then surged 73.71% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $72.8 million in 2021, then increased by 10.74% to $80.6 million in 2022, then surged by 40.34% to $113.1 million in 2023, then soared by 48.24% to $167.7 million in 2024, then grew by 13.35% to $190.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $190.1 million in Q4 2025, $189.2 million in Q3 2025, and $188.4 million in Q2 2025.